🔴 Intravenous Infusions is trading 4.17% down with no confirmed catalyst

Intravenous Infusions is trading at GHS 0.69, down 4.17%, with no confirmed company-specific catalyst.

• The September 4, 2026 decline remains unexplained in available coverage.
• Reports discuss Zagadat Capital’s 17.31% stake, acquired through May open-market purchases, but do not link it to the decline.
• Broader market indices were flat on September 7, 2026, offering no clear macro explanation.